Daiichi Sankyo out-licenses cancer candidate DS-6051

18 December 2018
daiichi-hq

Japanese drugmaker Daiichi Sankyo (TYO: 4568) has entered into a worldwide exclusive license agreement with USA-based AnHeart Therapeutics for DS-6051, Daiichi Sankyo’s selective ROS1/NTRK inhibitor, currently in Phase I development in the USA and Japan.

While Daiichi Sankyo and AnHeart will collaborate to continue two ongoing Phase I studies, AnHeart will be responsible for further development of DS-6051 worldwide. Daiichi Sankyo will receive an upfront payment and is eligible for clinical, regulatory and sales milestone payments, as well as royalties on worldwide net sales of DS-6051.

Financial terms of the agreement were not disclosed, but Daiichi Sankyo’s shares closed down 1.28% at 3,995 yen today.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical